TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Soleno Therapeutics today and set a price target of $115.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Buy rating due to a combination of factors, including an update to the SLNO model in anticipation of the company’s Q2 earnings. The revision includes an increased estimate for Q2 Vykat XR sales, aligning with the company’s preliminary figures of $31-33 million.
Furthermore, the analyst has raised the 2025 and peak sales projections to $130 million and $2.7 billion, respectively. These adjustments have led to an increase in the discounted cash flow-based price target to $115 from the previous $110, reinforcing the Buy rating.
In another report released on July 11, Robert W. Baird also maintained a Buy rating on the stock with a $121.00 price target.